桂龙咳喘宁品牌怎么样 申请店铺

我要投票 桂龙咳喘宁在医疗器械行业中的票数:652 更新时间:2026-01-03
桂龙咳喘宁是哪个国家的品牌?「桂龙咳喘宁」是桂龙药业(安徽)有限公司旗下著名品牌。该品牌发源于安徽省马鞍山市,由创始人Stephen John Coplin在2003-11-25期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力桂龙咳喘宁品牌出海!将品牌入驻外推网,定制桂龙咳喘宁品牌推广信息,可以显著提高桂龙咳喘宁产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

桂龙咳喘宁怎么样

桂龙咳喘宁,知名咳嗽药品牌,成立于1989年,高新技术企业,中药呼吸系统和咽喉品类领域领先企业,集研发/生产/销售于一体的中药企业


桂龙药业成立于1989年,是集研发、生产、销售为一体的中药行业企业。桂龙,取自谐音“贵”“隆”,意为富贵华荣兴旺发达。且“桂”,有桂树四季翠绿,香飘万里而古朴典雅,是传统中药的化身;“龙”,象征着东方文化与蓄势勃发的力量。

公司拥有员工约1000人,总部位于福建省厦门市,在安徽省马鞍山市和山西省忻州市设有两个生产基地,总占地面积11万平方米,建筑面积近4万平方米,均为现代化的花园式GMP工厂。 桂龙药业在全国设立27个销售办事处,拥有500人的销售团队,销售人员有效管理近6万家零售终端门店,产品覆盖全国近三十万家零售药店,以及全国所有主流连锁药店。

2003年经当涂县委、县人大招商引资在当涂经济开发区征地120亩,投资5000万元,建立了一座符合GMP要求的生产企业——桂龙药业(安徽)有限公司。公司目前拥有国药准字号品种31个,主要生产经营范围为:片剂、胶囊剂、颗粒剂、煎膏剂、及生产加工、经营糖果。其主导产品主要有:慢严舒柠牌清喉利咽颗粒、桂龙咳喘宁胶囊、新生化颗粒、复方柴胡安神颗粒、好爽糖等。科技创新、管理创新、岗位创新、市场创新是企业发展的原动力。科技人员占员工比例36%以上。公司拥有的技术研发中心和检测中心,保障了公司科技的可持续发展,保障了药品的质量和药品的安全。

桂龙专注于中药呼吸系统和咽喉品类领域,创立了国内呼吸系统和咽喉领域两个品牌“桂龙”牌、“慢严舒柠”牌。

“有健康就有桂龙,桂龙药业、健康事业”是桂龙药业的宗旨;品牌战略、人才战略、创新战略是桂龙发展的三个支撑;“敬业”、“诚信”、“责任”、“创新”是桂龙发展的核心理念。随着企业的发展壮大,桂龙药业现有的生产与研发平台不足以支撑桂龙药业未来若干年的迅速持续发展,为此桂龙药业决定在当涂经开区征地数百亩,以国内专业的制药技术和工艺装备,打造一个集生物医药生产和研究开发于一体的现代化医药产业园,以此支撑桂龙未来十多年的长足发展和技术创新、科技进步。


Guilong Kechuanning, a famous cough medicine brand, was founded in 1989. It is a high-tech enterprise, a leading enterprise in the field of traditional Chinese medicine respiratory system and throat category. Guilong pharmaceutical, a traditional Chinese medicine enterprise integrating R & D, production and sales, was founded in 1989. It is a traditional Chinese Medicine enterprise integrating R & D, production and sales. Guilong, from the homonym "Gui" and "long", means prosperity and prosperity. And "Gui" is the embodiment of traditional Chinese medicine, which has four seasons of green, fragrant and elegant, and "long" symbolizes the power of Oriental culture and vigorous development. The company has about 1000 employees and its headquarter is located in Xiamen City, Fujian Province. It has two production bases in Maanshan City, Anhui Province and Xinzhou City, Shanxi Province, covering a total area of 110000 square meters and a building area of nearly 40000 square meters, all of which are modern garden GMP factories. Guilong pharmaceutical has 27 sales offices in China, with a sales team of 500 people. The sales staff effectively manage nearly 60000 retail terminal stores, covering nearly 300000 retail pharmacies and all mainstream chain pharmacies in China. In 2003, Dangtu County Party committee and County People's Congress invested 120 mu of land in Dangtu economic development zone and invested 50 million yuan to establish a GMP compliant production enterprise - Guilong Pharmaceutical (Anhui) Co., Ltd. At present, the company has 31 varieties of State Pharmaceutical quasi brand, the main production and business scope are: tablets, capsules, granules, decoctions, as well as the production, processing and operation of candy. Its main products are: Manyan shuning brand Qinghou Liyan granules, Guilong Kechuanning capsule, xinbiochemical granules, compound Bupleurum Anshen granules, haoshuangtang, etc. Technological innovation, management innovation, post innovation and market innovation are the driving force of enterprise development. Science and technology personnel account for more than 36% of employees. The technology R & D center and testing center of the company ensure the sustainable development of the company's science and technology and the quality and safety of drugs. Focusing on the field of respiratory system and throat category of traditional Chinese medicine, Guilong has established two domestic brands in the field of respiratory system and throat, "Guilong" brand and "slow, strict, shuning" brand. The aim of Guilong pharmaceutical industry is to "have health, Guilong pharmaceutical industry and health cause"; brand strategy, talent strategy and innovation strategy are the three supports for the development of Guilong; dedication, integrity, responsibility and innovation are the core concepts for the development of Guilong. With the development of enterprises, the existing production and R & D platform of Guilong pharmaceutical industry is not enough to support the rapid and sustainable development of Guilong pharmaceutical industry in the next few years. Therefore, Guilong pharmaceutical industry decided to take hundreds of mu of land in Dangtu Economic Development Zone to build a modern pharmaceutical industrial park integrating biological pharmaceutical production and research and development with domestic professional pharmaceutical technology and process equipment, so as to support Guilong pharmaceutical industry Long's considerable development and technological innovation and scientific and technological progress in the next ten years.

本文链接: https://brand.waitui.com/0d765d197.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

创历史新高!2025年中国航天发射次数达92次

记者从国家航天局获悉,2025年,我国在载人航天、深空探测、商业航天等领域完成多项突破,实现多个首次。2025年,中国航天全年发射次数达到92次,创历史新高。 (央视新闻)

2小时前

元旦假期,敦煌莫高窟客流同比上涨约30%

敦煌研究院文化弘扬部部长雷政广:从预约数据来看,今年莫高窟元旦假期的游客,增幅应该在30%左右。冬春旅游季,莫高窟的游客主要是以年轻人为主,另外散客占了90%以上的比例。同时省外游客和入境游客,增幅也比较突出。(新浪财经)

2小时前

元旦后陆续入市的公募资金规模在430亿元以上

2026年市场徐徐展开,截至2025年12月31日,元旦后陆续入市的公募资金规模在430亿元以上。一是拟于元旦后上市的16只ETF,合计资金规模近50亿元;二是于2025年11月后成立的60多只处于建仓初期的主动权益基金,合计规模约为380多亿元。 券商中国记者采访了解到,新年上市ETF的持有人,以个人投资者居多,不少产品的个人投资者持有份额占比在90%以上。从底层资金来源看,根据机构预测,居民储蓄资金入市潜力巨大。2026年非定存投资领域有望额外新增2万亿元—4万亿元左右的活化资金。 受访人士对券商中国记者表示,2026年股票投资有望继续领跑,期待居民储蓄能更显著进入股票市场。2026年科技投资难度将大于2025年,超额收益将更依赖于对产业节奏的精准把握和个股的深度甄别,挑战增加,但结构性机遇依然丰富。(e公司)

2小时前

Netflix收购华纳后拟将上映期缩至17天

1月2日,有消息称流媒体巨头Netflix希望在完成对华纳兄弟的收购后,将华纳兄弟电影的院线独占放映期缩短至17天,这一做法引发传统影院及好莱坞电影创作者的担忧。媒体称,在讨论《怪奇物语》第五季大结局院线放映表现时,好莱坞业内对Netflix所称的“行业标准放映窗口”表达了疑虑。消息人士称,Netflix一直主张17天的院线窗口期,而包括AMC在内的院线方则坚持认为应维持在目前常见的45天左右。尽管Netflix尚未最终确定此政策,且未来可能与影院院线协商出一个介于17至45天之间的折中方案,但业内普遍预期,围绕窗口期的谈判将充满张力,而Netflix的核心重点无疑是巩固其流媒体业务。(格隆汇)

2小时前

25年飞天茅台散瓶批价跌至1495元/瓶

“今日酒价”披露的最新批发参考价显示,1月3日,25年飞天茅台原箱报1505元/瓶,较上一日降20元;25年飞天茅台散瓶报1495元/瓶,较上一日降15元。(格隆汇)

2小时前

本页详细列出关于桂龙咳喘宁的品牌信息,含品牌所属公司介绍,桂龙咳喘宁所处行业的品牌地位及优势。
咨询